OSLO, Norway, Aug. 20, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces the appointment of Dr Lars Nieba as Chief Technology Officer and a
member of the executive management team. Dr Nieba brings 20 years
of leadership experience in the development of multiple
pharmaceutical product candidates and innovative technologies. His
role at Nordic Nanovector will be to oversee all Chemistry,
Manufacturing and Controls (CMC) strategic and operational aspects
of Betalutin® and all other pharmaceutical products developed by
the company.
Dr Nieba will join Nordic Nanovector on 1
December 2019 from Bayer AG, where he served as VP and
Strategic Product Lead, responsible for driving Bayer's CMC
strategy related to CMC product development, product supply and
life cycle management of certain of its products (e.g. EYLEA®). He
joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche
Ltd., at which he held leadership roles in clinical supply
planning, biologics technology and technical business development
biologics.
Dr Nieba gained a PhD from the Max-Planck-Institute for
Biochemistry, München and Institute for Biochemistry at the
University of Zürich, and an Executive MBA; University of St.
Gallen, Switzerland. He holds dual
Swiss/German nationality and is a Swiss resident.
Eduardo Bravo, Nordic
Nanovector's Chief Executive Officer, said, "Lars is an important
hire for Nordic Nanovector, bringing valuable complementary
expertise to the executive team. He will play a crucial role in
refining and executing our CMC strategy for Betalutin® in
non-Hodgkin's lymphoma as well as for the other assets in our
emerging pipeline of targeted radioimmunotherapies. We are pleased
to welcome Lars to the team."
Lars Nieba commented: "I am delighted to be joining Nordic
Nanovector. Betalutin is a very exciting new treatment, since this
novel targeted radioimmunotherapy offers a clearly differentiated
therapy option for patients with non-Hodgkin's lymphoma. I look
forward to using my knowledge and expertise to make an important
contribution to Nordic Nanovector's future success and to ensure
that we are well prepared for regulatory filings for Betalutin®,
both in the USA and Europe."
EYLEA® is a registered trademark of Regeneron
Pharmaceuticals, Inc.
For further information, please contact:
IR
enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David
Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a
novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an
indication with substantial unmet medical need, representing a
growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends
to retain marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets. Further
information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking statements.
These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances, since they
relate to events and depend on circumstances that will occur in the
future and which, by their nature, will have an impact on Nordic
Nanovector's business, financial condition and results of
operations. The terms "anticipates", "assumes", "believes", "can",
"could", "estimates", "expects", "forecasts", "intends", "may",
"might", "plans", "should", "projects", "targets", "will", "would"
or, in each case, their negative, or other variations or comparable
terminology are used to identify forward-looking statements. These
forward-looking statements are not historic facts. There are a
number of factors that could cause actual results and developments
to differ materially from those expressed or implied in the
forward-looking statements. Factors that could cause these
differences include, but are not limited to, risks associated with
implementation of Nordic Nanovector's strategy, risks and
uncertainties associated with the development and/or approval of
Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise
Betalutin®, technology changes and new products in Nordic
Nanovector's potential market and industry, Nordic Nanovector's
freedom to operate (competitors patents) in respect of the products
it develops, the ability to develop new products and enhance
existing products, the impact of competition, changes in general
economy and industry conditions, and legislative, regulatory and
political factors. No assurance can be given that such expectations
will prove to have been correct. Nordic Nanovector disclaims any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
This information is subject to a duty of disclosure pursuant to
Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-appoints-dr-lars-nieba-as-chief-technology-officer,c2884271
View original
content:http://www.prnewswire.com/news-releases/nordic-nanovector-appoints-dr-lars-nieba-as-chief-technology-officer-300904152.html
SOURCE Nordic Nanovector